| pubmed-article:10818496 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10818496 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:10818496 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:10818496 | lifeskim:mentions | umls-concept:C0027882 | lld:lifeskim |
| pubmed-article:10818496 | lifeskim:mentions | umls-concept:C0007806 | lld:lifeskim |
| pubmed-article:10818496 | lifeskim:mentions | umls-concept:C0876926 | lld:lifeskim |
| pubmed-article:10818496 | lifeskim:mentions | umls-concept:C0002716 | lld:lifeskim |
| pubmed-article:10818496 | lifeskim:mentions | umls-concept:C0599732 | lld:lifeskim |
| pubmed-article:10818496 | lifeskim:mentions | umls-concept:C0388060 | lld:lifeskim |
| pubmed-article:10818496 | lifeskim:mentions | umls-concept:C0758515 | lld:lifeskim |
| pubmed-article:10818496 | pubmed:dateCreated | 2000-6-2 | lld:pubmed |
| pubmed-article:10818496 | pubmed:abstractText | The increased risk for Alzheimer's Disease (AD) associated with traumatic brain injury (TBI) suggests that environmental insults may influence the development of this age-related dementia. Recently, we have shown that the levels of the beta-amyloid peptide (A beta 1-42) increase in the cerebrospinal fluid (CSF) of patients after severe brain injury and remain elevated for some time after the initial event. The relationships of elevated A beta with markers of blood-brain barrier (BBB) disruption, inflammation, and nerve cell or axonal injury were evaluated in CSF samples taken daily from TBI patients. This analysis reveals that the rise in A beta 1-42 is best correlated with possible markers of neuronal or axonal injury, the cytoskeletal protein tau, neuron-specific enolase (NSE), and apolipoprotein E (ApoE). Similar or better correlations were observed between A beta 1-40 and the three aforementioned markers. These results imply that the degree of brain injury may play a decisive role in determining the levels of A beta 1-42 and A beta 1-40 in the CSF of TBI patients. Inflammation and alterations in BBB may play lesser, but nonetheless significant, roles in determining the A beta level in CSF after brain injury. | lld:pubmed |
| pubmed-article:10818496 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10818496 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10818496 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10818496 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:10818496 | pubmed:issn | 0077-8923 | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:MehtaP DPD | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:WatsonM DMD | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:KuoY MYM | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:SpiegelKK | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:KossmannTT | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:Morganti-Koss... | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:EvansL MLM | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:EmmerlingM... | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:RoherA EAE | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:StahelP FPF | lld:pubmed |
| pubmed-article:10818496 | pubmed:author | pubmed-author:RabyC ACA | lld:pubmed |
| pubmed-article:10818496 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10818496 | pubmed:volume | 903 | lld:pubmed |
| pubmed-article:10818496 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10818496 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10818496 | pubmed:pagination | 118-22 | lld:pubmed |
| pubmed-article:10818496 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:meshHeading | pubmed-meshheading:10818496... | lld:pubmed |
| pubmed-article:10818496 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10818496 | pubmed:articleTitle | Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury. | lld:pubmed |
| pubmed-article:10818496 | pubmed:affiliation | Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105, USA. mark.emmerling@wl.com | lld:pubmed |
| pubmed-article:10818496 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10818496 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10818496 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10818496 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10818496 | lld:pubmed |
